Navigation Links
Statement From Michael Hansen, CEO of Elsevier's Health Sciences Division, Regarding Australia Based Sponsored Journal Practices Between 2000 and 2005
Date:5/7/2009

PHILADELPHIA, Pennysylvania, May 7 /PRNewswire-FirstCall/ -- Elsevier, one of the world's leading publishers of scientific, technical, and medical (STM) information products and services, announced today that Michael Hansen, CEO of Elsevier's Health Sciences Division, issued the following statement in light of recent allegations of improper Australia based sponsored journal publication practices between 2000 and 2005:

"Elsevier prides itself on operating its business in the most ethical, honest and transparent manner possible. We have been stewards of the scientific record for more than 125 years and we take our role in advancing medical and scientific research seriously.

It has recently come to my attention that from 2000 to 2005, our Australia office published a series of sponsored article compilation publications, on behalf of pharmaceutical clients, that were made to look like journals and lacked the proper disclosures. This was an unacceptable practice, and we regret that it took place.

We are currently conducting an internal review but believe this was an isolated practice from a past period in time. It does not reflect the way we operate today. The individuals involved in the project have long since left the company. I have affirmed our business practices as they relate to what defines a journal and the proper use of disclosure language with our employees to ensure this does not happen again.

We will continue to partner with all scientists and clinical investigators, including those in the pharmaceutical industry, to help communicate the findings of high-quality, peer-reviewed medical research. We have strict disclosure rules in place so that readers are aware of any financial interests behind a specific article or journal, or when entire compilation products are created for pharmaceutical marketing purposes.

I understand this issue has troubled our communit
'/>"/>

SOURCE Elsevier
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. VaxGen Files 2006 Financial Statements and Provides Cash Update
2. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
3. Anacor Files Registration Statement for Initial Public Offering
4. IsoTis Files Definitive Proxy Statement
5. MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock
6. Statement on Direct-To-Consumer Genetic Testing
7. Coherent Announces Restatement Related to Stock-Based Compensation
8. XTL Biopharmaceuticals: AGM/EGM Statements
9. Statement from GPhA President and CEO Kathleen Jaeger on FDAs Generic Initiative
10. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
11. CCPM Issues Statement on FDAs GIVE Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2012)... 21, 2012 The Houston Technology ... accelerator, hosted its 9th annual gala, "A ... local entrepreneurs that have made a significant impact ... revolutionary technologies. The Houston Technology Center ... as this year,s honoree. As the Founder and CEO ...
(Date:5/18/2012)... -- Champions Oncology Inc. (OTC: CSBR) announced today ... Amendment (CLIA) certification from the Maryland Department of ... Quality required for the company to conduct medical ... Ronnie Morris, MD commented, "Obtaining CLIA approval is ... validates the quality of our laboratory, which operates ...
(Date:5/17/2012)... May 16, 2012  In an effort to voice ... diseases (PIDD), the Immune Deficiency Foundation (IDF) offered oral ... Drug Administration (FDA) public hearing on draft guidance of ... (Ig) therapies from the biosimilars pathways in order to ... PIDD occurs in people born with an immune ...
(Date:5/16/2012)... May 16, 2012 Reportlinker.com announces ... available in its catalogue:   ... Industry http://www.reportlinker.com/p0459168/Global-Anti-Microbial-Coatings-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Paint_and ... the US market for Anti-microbial Coatings in ... Indoor Air Quality, and Medical Devices. Annual ...
Breaking Biology Technology:Leading Technology Incubator Honors Extraordinary Entrepreneurs 2Leading Technology Incubator Honors Extraordinary Entrepreneurs 3Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities 2Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities 3Immune Deficiency Foundation Urges FDA To Exempt Immunoglobulin From Biosimilars Pathway 2Global Anti-Microbial Coatings Industry 2Global Anti-Microbial Coatings Industry 3Global Anti-Microbial Coatings Industry 4Global Anti-Microbial Coatings Industry 5Global Anti-Microbial Coatings Industry 6Global Anti-Microbial Coatings Industry 7Global Anti-Microbial Coatings Industry 8Global Anti-Microbial Coatings Industry 9Global Anti-Microbial Coatings Industry 10Global Anti-Microbial Coatings Industry 11Global Anti-Microbial Coatings Industry 12Global Anti-Microbial Coatings Industry 13
... On January 7,2008, Signalife received a deficiency letter ... it advised that Signalife would need to,comply with ... listing under AMEX Rules 1003(a)(iii). This notification was,triggered ... less than,$50 million, which previously exempted Signalife from ...
... New Agent for CLL Patients Approved by the FDA ... Cephalon, Inc. (Nasdaq:,CEPH) today announced that the U.S. Food ... Injection for the,treatment of patients with chronic lymphocytic leukemia ... American Cancer Society,estimates that more than 15,000 new cases ...
... study setup and launch..., WAYLAND, Mass., March ... clinical trials software, announces the,launch of its Trident ... unique parameter driven + custom pluggable design,leaps ahead ... a new era,of needed scalability, productivity, and ease-of-use ...
Other Biology Technology:AMEX Notifies Signalife That It Has Accepted Signalife's Plan of Compliance 2Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia 2Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia 3Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia 4Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia 5Tourtellotte's New Trident IWR(TM) Eliminates 12-Week Study Setup Lead Time for Clinical Trials 2Tourtellotte's New Trident IWR(TM) Eliminates 12-Week Study Setup Lead Time for Clinical Trials 3
(Date:5/21/2012)... University of Singapore,s (NUS) Department of Biological Sciences and ... a compound that is undergoing preclinical trials as a ... and stop them from growing into a tumour. This ... the first time a research group has provided evidence ... , Building on the new findings, the NUS team ...
(Date:5/21/2012)... teams of Australian and US scientists has found there ... Antarctic Bottom Water found off the coast of Antarctica.,Comparing ... Southern Ocean marine science voyage to historical data dating ... much as a 60 per cent reduction in the ... that drives global ocean currents. , In an intensive ...
(Date:5/20/2012)... (HDAC) inhibitor panobinostat is able to target and ... study published in BioMed Central,s open access journal ... University Health Sciences Center have shown that panobinostat ... reduce tumor growth in mice. , Approximately 15% ... be triple negative. These aggressive tumours are missing ...
Breaking Biology News(10 mins):Novel discovery by NUS scientists paves the way for more effective treatment of cancers 2Latest Southern Ocean research shows continuing deep ocean change 2Latest Southern Ocean research shows continuing deep ocean change 3Blocking DNA: HDAC inhibitor targets triple negative breast cancer 2San Diego State Offers Project Management Programs Beginning in January 61681 1San Diego State Offers Project Management Programs Beginning in January 61681 2Hobbits are a new human species according to the statistical analysis of fossils 10800 1Hobbits are a new human species according to the statistical analysis of fossils 10800 2Marrone Bio Innovations Named an IC20 Company 14914 1Marrone Bio Innovations Named an IC20 Company 14914 2
... Institute on Drug Abuse (NIDA), part of the National ... genes that might increase a person’s ability to abstain ... George Uhl at NIDA’s Intramural Research Program and a ... for Nicotine and Smoking Cessation Research at Duke University ...
... MIT have created an ocean model so realistic that the ... in population patterns that precisely mimic their real-world counterparts. , ... the vast diversity of the invisible forests living in our ... half the oxygen we breathe on Earth. And it does ...
... of millipede was recently discovered by a Northern Arizona ... researcher. , J. Judson Wynne, with the Department ... with the U.S. Geological Survey's Southwest Biological Center, and ... of Land Management (BLM), collected specimens leading to the ...
Other Biology News:NIDA study identifies genes that might help some people abstain from smoking 2MIT's ocean model captures diversity of underwater forests 2MIT's ocean model captures diversity of underwater forests 3Discovery of new cave millipedes casts light on Arizona cave ecology 2Discovery of new cave millipedes casts light on Arizona cave ecology 3